Please Wait...

Lipoprotein A Lp(a)

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Lp(a) is a macromolecular complex composed of one molecule of Low-Density Lipoprotein (LDL) containing apolipoprotein B100 and one molecule of apolipoprotein(a). Lp(a) is synthesized by the liver and its assembly occurs at the hepatocyte cell membrane surface. Lp(a) has been shown to promote thrombosis, by preventing the conversion of plasminogen to plasmin and to participate to wound healing and tissue repair (Riches and Porter, 2012). Lp(a) has also been described as an acute-phase reactant in various disorders. High levels of Lp(a) correlates with an increased risk of cardiovascular diseases and are found in patients with Rheumatoid Arthritis (Govindan et al., 2015; Saeedi and Frohlich, 2016).

Bioclinica Lab employs uses the quantitative immunoturbidimetry method for the measurement of human Lp(a) in serum.

Govindan, K.P.S., Basha, S., Ramesh, V., Kumar, C.N., and Swathi, S. (2015). A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects. J. Pharm. Bioallied Sci. 7, S22–S25.

Riches, K., and Porter, K.E. (2012). Lipoprotein(a): Cellular Effects and Molecular Mechanisms. Cholesterol 2012, e923289.

Saeedi, R., and Frohlich, J. (2016). Lipoprotein (a), an independent cardiovascular risk marker. Clin. Diabetes Endocrinol. 2, 7.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen